The Role of the Interleukin-6/gp130 Signaling Pathway in Bone Metabolism

Vitamins and Hormones

Volumn 74, Issue , 2006, Pages 341-355

  Liu, Xin Hua ^a   Kirschenbaum, Alexander ^a   Yao, Shen ^a   Levine, Alice C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 6;

ANIMAL; BONE; BONE REMODELING; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BONE AND BONES; BONE REMODELING; CYTOKINE RECEPTOR GP130; HUMANS; INTERLEUKIN-6; RECEPTOR CROSS-TALK; SIGNAL TRANSDUCTION;

EID: 33947724217     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0083-6729(06)74014-6     Document Type: Review

References (73)

1. Aubin J.E. Advances in the osteoblast lineage. Biochem. Cell Biol. 76 (1998) 899-910
2. Bellido T., Jilka R.J., Boyce B.F., Girasole G., Broxmeyer H., Dalrymple S.A., Murray R., and Manolagas S.C. Regulation of interleukin-6, osteo-clastogenesis and bone mass by androgens: The role of the androgen receptor. J. Clin. Invest. 95 (1995) 2886-2895
3. Bellido T., Borba V.Z., Roberson P., and Monolagas S.C. Activation of the Janus kinase/STAT signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. Endocrinology 138 (1997) 3666-3676
4. waf-1 gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effect on human osteoblastic cells. J. Biol. Chem. 273 (1998) 21137-21144
5. Brandstrom H., Bjorkman T., and Ljunggren O. Regulation of osteopro-tegerin secretion from primary cultures of human bone marrow stromal cells. Biochem. Biophys. Res. Commun. 280 (2001) 831-835
6. Erices A., Conget P., Rojas C., and Minguell J. gp130 activation by soluble interleukin 6 receptor/interleukin 6 enhances osteoblastic differentiation of human bone marrow-derived from mesenchymal stem cells. Exp. Cell Res. 180 (2002) 24-32
7. Ferrari S.L., Garnero P., Emond S., Montgomery H., Humphries S.E., and Greenspan S.L. A functional polymorphic variant in the interleukin-6 gene promoter associated with low bone resorption in postmenopausal women. Arthritis Rheum. 44 (2001) 196-201
8. Fohr B., Dunstan C.R., and Seibel M.J. Markers of bone remodeling in metastatic bone disease. J. Clin. Endo & Meta 88 (2003) 5059-5075
9. Forwood M.R. Inducible COX-2 mediates the induction of bone formation by mechanical loading in vivo. J. Bone Miner. Res. 11 (1996) 1688-1693
10. Fukuta T. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: Involvement of STAT3 in anti-apoptosis. Immunity 5 (1996) 449-460
11. Galien R., Evans H., and Garcia T. Involvment of CCAAT/enhancer-binding protein and NF-κB binding sites in IL-6 promoter inhibition by estrogens. Mol. Endocrinol. 10 (1996) 713-722
12. Gao Y., Morita I., Maruo N., Kubota T., Murota S., and Aso T. Expression of IL-6 receptor and gp130 in mouse bone marrow cells during osteoclast differentiation. Bone 22 (1998) 487-493
13. Gorny G., Shaw A., and Oursler M.J. IL-6, LIF, and TNFα regulation of GM-CSF inhibition of osteoclastogenesis in vitro. Exp. Cell Res. 294 (2004) 149-158
14. Greenfield E.M., Shaw S.M., Gornik S.A., and Banks M.A. Adenyl cyclase and IL-6 are downstream effectors of parathyroid hormone regulating in stimulation of bone resorption. J. Clin. Invest. 96 (1995) 1238-1244
15. Grey A., Mitnick M.-A., Masiukiewicz U., Sun B.H., Rudikoff S., Jilka R.L., Manolagas S.C., and Insogna K. A role for IL-6 in parathyroid hormone-induced bone resorption in vivo. Endocrinology 140 (1999) 4683-4690
16. 2 and calcemic hormones of interleukin-6 in stromal/osteoblastic cells. Biochem. Biophys. Res. Commun. 270 (2000) 1080-1085
17. Heymann D., and Rousselle A.-V. gp130 cytokine family and bone cells. Cytokine 12 (2000) 1455-1468
18. Holt I., Davie M.W.J., and Marshall M.J. Osteoclast are not the major source of interleukin-6 in mouse parietal bone. Bone 18 (1996) 221-226
19. Hong S.H., Ondrey F.C., Avis I.M., Chen Z., Loukinova E., Cavanaugh Jr. P.F., Waes C.V., and Mulshine J.L. Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine interleukin-6: A general role for inflammation?. FASEB J. 14 (2000) 1499-1507
20. Hughes F.J., and Howells G.L. Interleukin-6 inhibits bone formation in vitro. Bone Miner. 21 (1993) 21-28
21. Jilka R.L., Hangoc G., Girasole G., Passeri G., Williams D.C., Abrams J.S., Boyce B., Broxmeyer H., and Manolagas S.C. Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 257 (1992) 88-91
22. Jilka R.L., Weinstein R.S., Bellido T., Parfitt A.M., and Manolagas S.C. Osteoblast programmed cell death (apoptosis): Modulation by growth factor and cytokines. J. Bone Miner. Res. 13 (1998) 793-802
23. Jimi E., Nakamura I., Amano H., Taguchi Y., Tsurakai T., Tamura M., Takahashi N., and Suda T. Osteoclst function is activated by osteoblastic cells through mechanism involving cell-to-cell contact. Endocrinology 137 (1996) 2187-2190
24. Kamimura D., Ishihara K., and Hirano T. IL-6 signal transduction and its physiological roles: The signal orchestration model. Rev. Physiol. Biochem. Pharmacol. 149 (2003) 1-38
25. Kishimoto T. The biology of interleukin-6. Blood 74 (1989) 1-10
26. Kishimoto T., Akira S., Narazaki M., and Taga T. Interleukin-6 family of cytokines and gp130. Blood 86 (1995) 1243-1254
27. 2: Cross-talk regulation by protein kinase C. Bone 22 (1998) 355-360
28. Kudo O., Fujikawa Y., Itonaga I., Sabokbar A., Torisu T., and Athanasou N.A. Proinflammatory cytokines (TNFα/IL-1α) induction of human osteoclast formation. J. Pathol. 198 (2002) 220-227
29. Kudo O., Sabokbar A., Pocock A., Itonaga I., Fujikawa Y., and Athanasou N.A. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32 (2003) 1-7
30. Kuehl W.M., and Bergsagel P.L. Multiple myeloma: Evolving genetic events and host interactions. Nature Rev. Cancer 1 (2002) 175-187
31. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., and Kotake S. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the OPG/RANKL/RANK interaction. J. Exp. Med. 191 (2000) 275-286
32. Lacey D.L., Timms E., Tan H.L., Keller M., Dunstan C.R., and Burgess T. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
33. Legrand-Poels S., Schoonbroodt S., and Piette J. Regulation of interleukin-6 gene expression by pro-inflammatory cytokines in a colon cancer cell line. Biochem. J. 349 (2000) 765-773
34. 2 receptor impairs osteoclastogenesis in vitro. Endocrinology 141 (2000) 2054-2061
35. 2 stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/gp130/STAT-3 signaling pathway. Biochem. Biophys. Res. Commun. 290 (2002) 249-255
36. 2 signaling system results in enhancement of osteoclastogenesis through effects on the OPG/RANKL/RANK system. Endocrinology 146 (2005) 1991-1998
37. Lowe C., Cornish J., Callon K., Martin T.J., and Reid L.R. Regulation of osteoblast proliferation by leukemia inhibitory factor. J. Bone Miner. Res. 6 (1991) 1277-1283
38. Lowik C.W., van der Pluijm G., Bloys H., Hoekman K., Bijvoet O.L.M., Aarden L.A., and Papapoulos S.A. Parathyroid hormone (PTH) and PTH- like protein (PLP) stimulate interleukin-6 production by osteogenic cells: A possible role of interleukin-6 in osteoclastogenesis. Biochem. Biophys. Res. Commun. 162 (1989) 1546-1552
39. Ludwig H., Nachbaur D.M., Fritz E., Krainer M., and Huber H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood 77 (1991) 2794-2795
40. Malik N., Haugen H.S., Modrell B., Shoyab M., and Clegg C. Development abnormalities in mice. Mol. Cell Biol. 15 (1995) 2349-2358
41. Manolagas S.C. The role of IL-6 type cytokines and their receptors in bone. Ann. N. Y. Acad. Sci. 840 (1998) 194-204
42. Manolagas S.C., and Jilka R.L. Bone marrow, cytokines, and bone remodeling: Emerging insights into the pathophysiology of osteoprosis. N. Engl. J. Med. 332 (1995) 305
43. Martin T.J., Romas E., and Gillespie M.T. Interleukins in the control of osteoclast differentiation. Crit. Rev. Eukary. Gene Expression 8 (1998) 107
44. 2 receptors in the pathogenesis of rheumatoid arthritis. J. Clin. Invest. 110 (2002) 651-658
45. Metcalf D., and Gearing G.P. Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor. Proc. Natl. Acad. Sci. USA 86 (1989) 5948-5952
46. 4-knockout mice. J. Biol. Chem. 275 (2000) 19819-19823
47. Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Yano K., Morinaga T., and Higashio K. RANK is the essential signaling receptor for osteoclast differention factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 253 (1998) 395-400
48. Nakashima T., Kobayashi Y., Yamasaki S., Kawakami A., Eguchi K., Sasaki H., and Sakai H. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-κB ligand: Modulation of the expression by osteotropic factors and cytokines. Biochem. Biophys. Res. Commun. 275 (2000) 768-775
49. Ni Z., Lou W., Leman E.S., and Gao A.C. Inhibition of constitutively activated Stat-3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res. 60 (2000) 1225-1228
50. O'Brien C.A., Lin S.C., Bellido T., and Manolagas S.C. Expression levels of gp130 in bone marrow stromal cells determine the magnitude of osteo-clastogenic signals generated by IL-6-type cytokines. J. Cell. Biochem. 79 (2000) 532-549
51. Ohlsson C., Bengtsson B.A., Isakasson O.G., Andreassen T.T., and Slootweg M.C. Growth hormone and bone. Endocr. Rev. 19 (1998) 55-79
52. Okada Y., Lorenzo J.A., Freeman A.M., Tomita M., Morham S.G., Raisz L.G., and Pilbeam C.C. COX-2 is required for maximal formation of osteoclast-like cells in culture. J. Clin. Invest. 105 (2000) 823-832
53. Ono K., Akatsu T., Murakami T., Kitamura R., Yamamoto M., Rokutanda M., Nagata N., and Kugai N. Involvement of cyclooxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. J. Bone Miner. Res. 17 (2002) 774-781
54. Otsuka T., Thacker J.D., and Hogge D.E. The effects of interleukin-6 and interleukin-3 on early hemotopoietic events in long-term cultures of human bone marrow. Exp. Hematol. 19 (1991) 1042-1048
55. Poli V., Balena R., Fattori E., Markatos A., Yamamoto M., Tanake H., Ciliberto G., Rodan G.A., and Costantini F. IL-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13 (1994) 1189-1196
56. Ragab A.A., Nalepka J.L., Bi Y., and Greenfield E.M. Cytokines synergistically induce osteoclast differentiation: Support by immortalized or normal calvarial cells. Am. J. Physiol. Cell Physiol. 283 (2002) C679-C687
57. Roodman G.D. Advances in bone biology: The osteoclast. Endocr. Rev. 17 (1996) 308-332
58. Rozen N., Ish-Shalom S., Rachmiel A., Stein H., and Lewinson D. IL-6 modulates trabecular and endochondral bone turnover in the nude mouse by stimulating osteoclast differentiation. Bone 26 (2000) 469-474
59. Simonet W.S., and Luthy R. OPG: A novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
60. Sims N.A., Jenkins B.J., Quinn J.M., Nakamura A., Glatt M., Gillespie M.T., Ernst M., and Martin T.J. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J. Clin. Invest. 113 (2004) 379-389
61. Stahl N., Farruggella T.J., Boulton T.G., Zhong Z., Darnell Jr. J.E., and Yancopoulos G.D. Choice of STATs and other substrates specified by modular tyrosin-based motifs in cytokine receptors. Science 267 (1995) 1349-1353
62. Steeve K.T., Marc P., Sandrine T., Heymann D., and Yannick F. IL-6, RANKL, TNFα/IL-1: Interactions in bone resorption pathophysiology. Cytokines Growth Factor Rev. 15 (2004) 49-60
63. Suda T., Takahashi N., Udagawa E., Jimi M.T., and Martin T.J. Modulation of osteoclast differentiation and function by the new members of the TNF receptor and ligand families. Endocr. Rev. 20 (1999) 345-357
64. 2 in periarticular osteoporosis of postmenopausal woman with rheumatoid arthritis. J. Bone Miner. Metab. 19 (2001) 89-96
65. 2 on bone mass in rat long bones and calvariae. J. Endocrinol. 156 (1998) 51-57
66. Taga T., and Kishimoto T. gp130 and the interleukin 6 family of cytokines. Annu. Rev. Immunol. 15 (1997) 797-819
67. Tagochi Y., Yamamoto M., Yamate T., Lin S.C., Mocharla H., DeTogni P., Nakayama N., Boyce B.F., Abe E., and Manolagas S.C. Interleukin-6-type cytokines stimulate meshenchymal progenitor differentiation toward the osteoblastic lineage. Proc. Assoc. Am. Physicians 110 (1998) 559-574
68. Tarura T., Udagawa N., Takahashi N., Miyaura C., Tanaka S., and Yamada Y. Soluble IL-6 receptor triggers osteoclast formation by IL-6. Proc. Natl. Acad. Sci. USA 90 (1993) 11924-11928
69. Udagawa N., Takahashi N., Katagiri T., Tamura T., Wada S., Findlay D.M., Martin T.J., Hirota H., Taga T., Kishimoto T., and Suda T. IL-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J. Exp. Med. 182 (1995) 1461-1468
70. Verbruggen A., De Clerck L.S., Bridts C.H., van Offel J.F., and Stevens W.J. Flow cytometric determination of interleukin-1β, interleukin-6 and tumor necrosis factor-α in monocytes of rheumatoid arthritis patients: Relation with parameters of osteoporosis. Cytokines 11 (1999) 869-874
71. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., et al. Osteoclast differentiation factor is a ligand for OPG/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95 (1998) 3597-3602
72. Zhang X., Morham S.G., Langenbach R., Young D.A., Xing L., Boyce B.F., Puzas E.J., Rosier R.N., O'Keefe R.J., and Schwarz E.M. Evidence for a direct role of cyclooxygenase-2 in implant wear debris induced osteolysis. J. Bone Miner. Res. 16 (2001) 660-669
73. Zhang X., Schwarz E.M., Young D.A., Puzas J., Rosier R.N., and O'Keefe R.J. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J. Clin. Invest. 109 (2002) 1405-1415